Status:
UNKNOWN
Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant
Lead Sponsor:
Rhode Island Hospital
Collaborating Sponsors:
Janssen Pharmaceutica N.V., Belgium
Emory University
Conditions:
Major Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety and efficacy of risperidone augmentation in patients who have failed to respond or only partially responded to an adequate trial of an antidepressant.
Detailed Description
Specific Aims: The goal of this study was to assess the safety and efficacy of risperidone augmentation in patients with major depression who failed to respond, or only partially responded, to an adeq...
Eligibility Criteria
Inclusion
- patients with major depression or partially remitted depression
- currently receiving an adequate trial of an antidepressant
Exclusion
- diagnosis of bipolar I or bipolar II disorder
- psychotic features
- substance dependence or abuse in the past three months
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00174577
Start Date
February 1 2003
End Date
February 1 2005
Last Update
September 15 2005
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University School of Medicine
Atlanta, Georgia, United States, 30329
2
Mood Disorders Program - Rhode Island Hospital
Providence, Rhode Island, United States, 02903